Stern M B, Freese A
Graduate Hospital Parkinson's Disease and Movement Disorders Center, Philadelphia, Pennsylvania 19146, USA.
Exp Neurol. 1997 Mar;144(1):2-3. doi: 10.1006/exnr.1996.6378.
Over the past 30 years, significant strides have been made toward improving symptomatic therapy of patients with Parkinson's disease. However, limitations persist, and the incremental improvement each new drug offers a patient yields only a minimal advantage therapeutically. Therefore, to alter meaningfully the natural course of this debilitating disorder, which becomes more prevalent each year in our society, significant novel therapeutic approaches must be tested. Genetic intervention in Parkinson's disease may offer an entirely different method for treating this disease in the future, based not only on symptomatic therapy, but also on neuroprotective and/or neuroregenerative therapy which would alter the natural history of relentless progression.
在过去30年里，帕金森病患者的症状治疗取得了显著进展。然而，局限性依然存在，每种新药给患者带来的渐进性改善在治疗上仅产生极小的优势。因此，为了切实改变这种使人衰弱的疾病的自然进程（这种疾病在我们的社会中每年都变得更加普遍），必须测试重大的新型治疗方法。对帕金森病的基因干预可能在未来提供一种完全不同的治疗该疾病的方法，这不仅基于症状治疗，还基于神经保护和/或神经再生治疗，而这将改变疾病无情进展的自然病程。
